Abstract
To the Editors: Itraconazole has been widely used in the treatment of fungal disease including chronic necrotising pulmonary aspergillosis (CNPA) 1, 2. Its use has been associated with occasional reports of adverse cardiovascular events including congestive heart failure 3, hypertension (HT) 4, premature ventricular contractions 5 and even ventricular fibrillation 6. However, these adverse effects have been considered to be uncommon, if not rare, occurrences. From September, 1992 to April, 2001, the US Food and Drug Administration received only 59 reports of potential cases of congestive heart failure with the administration of itraconazole 3. Despite the recommendation …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
